| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | KPRX | Common Stock | Conversion of derivative security | $4.09M | +853K | +25.47% | $4.80 | 4.2M | Jul 27, 2021 | See Footnote | F1 |
| transaction | KPRX | Common Stock | Sale | -$516K | -73.1K | -1.74% | $7.06 | 4.13M | Jul 27, 2021 | See Footnote | F1, F2 |
| transaction | KPRX | Common Stock | Sale | -$2.98M | -462K | -11.19% | $6.45 | 3.66M | Jul 27, 2021 | See Footnote | F1, F4 |
| transaction | KPRX | Common Stock | Sale | -$3.97M | -729K | -19.9% | $5.44 | 2.94M | Jul 27, 2021 | See Footnote | F1, F5 |
| transaction | KPRX | Common Stock | Sale | -$2.44M | -532K | -18.13% | $4.59 | 2.4M | Jul 27, 2021 | See Footnote | F1, F6 |
| transaction | KPRX | Common Stock | Sale | -$2.21M | -582K | -24.2% | $3.80 | 1.82M | Jul 27, 2021 | See Footnote | F1, F7 |
| transaction | KPRX | Common Stock | Sale | -$1.23M | -375K | -20.61% | $3.28 | 1.45M | Jul 28, 2021 | See Footnote | F1, F8 |
| transaction | KPRX | Common Stock | Sale | -$1.2M | -400K | -27.66% | $3.00* | 1.05M | Jul 29, 2021 | See Footnote | F1, F9 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | KPRX | Series C Convertible Preferred Stock | Conversion of derivative security | $0 | -4.09K | -100% | $0.00* | 0 | Jul 27, 2021 | Common Stock | 853K | $4.80 | See Footnote | F1, F3 |
| Id | Content |
|---|---|
| F1 | The reported securities of EyeGate Pharmaceuticals, Inc. (the "Issuer") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital ("Mr. Boyd", and collectively with the Master Fund and Armistice Capital, the "Reporting Persons"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.002 to $7.1559, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (5), (6), (7), (8) and (9) to this Form 4. |
| F3 | The Series C Convertible Preferred Stock has no expiration date and was convertible at any time at the option of the Master Fund. |
| F4 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.0052 to $6.9970, inclusive. |
| F5 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.1066 to $5.9464, inclusive. |
| F6 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.0011 to $4.9908, inclusive. |
| F7 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.5852 to $3.9402, inclusive. |
| F8 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.1713 to $3.4093, inclusive. |
| F9 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.85 to $3.24, inclusive. |
Each of the Master Fund and Armistice Capital may be deemed a director by deputization of the Issuer by virtue of the fact that Steven Boyd and Keith Maher, representatives of the Master Fund and Armistice Capital, currently serve on the Issuer's board of directors